Sanofi and Regeneron Report Positive Asthma Trial Results
October 31 2017 - 8:57AM
Dow Jones News
By Sonia Amaral Rohter
Sanofi SA (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN) on
Tuesday reported positive results from their phase 3 trial
investigating the use of co-developed drug dupilumab as a
steroid-dependent asthma treatment.
The trial studied the use of dupilumab in patients with severe
chronic asthma who rely on oral corticosteroids to help control
symptoms and reduce asthma attacks. Oral corticosteroids can have
serious side effects, such as osteoporosis or diabetes.
Dupilumab, also known as Dupixent, is already approved to treat
eczema.
France's Sanofi says that participants who received dupilumab in
conjunction with standard therapies were able to reduce their use
of maintenance oral corticosteroids by 70% on average, experienced
59% fewer asthma attacks, and improved their lung function.
Dupilumab, which is being jointly developed by Sanofi and
Regeneron, works by blocking a pathway that leads to inflammation.
Sanofi is studying its use in other inflammatory diseases such as
pediatric eczema and food allergies.
The French company plans to apply for a supplemental biologics
license from the U.S. Food and Drug Administration by the end of
this year that relates to the use of dupilumab as an asthma
treatment.
According to the U.S. Centers for Disease Control and
Prevention, approximately 18.4 million adults and 6.2 million
children suffer from asthma in the U.S.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
October 31, 2017 08:42 ET (12:42 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2023 to Sep 2024